Oncolytic virotherapy for breast cancer treatment

Samia M. O’bryan, James Michael Mathis

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Breast cancer continues to be a leading cause of mortality among women. While at an early stage, localized breast cancer is easily treated; however, advanced stages of disease continue to carry a high mortality rate. The discrepancy in treatment success highlights that current treatments are insufficient to treat advanced-stage breast cancer. As new and improved treatments have been sought, one therapeutic approach has gained considerable attention. Oncolytic viruses are uniquely capable of targeting cancer cells through intrinsic or engineered means. They come in many forms, mainly from four major virus groups as defined by the Baltimore classification system. These vectors can target and kill cancer cells, and even stimulate immunotherapeutic effects in patients. This review discusses not only individual oncolytic viruses pursued in the context of breast cancer treatment but also the emergence of combination therapies with current or new therapies, which has become a particularly promising strategy for treatment of breast cancer. Overall, oncolytic virotherapy is a promising strategy for increased treatment efficacy for advanced breast cancer and consequently provides a unique platform for personalized treatments in patients.

Original languageEnglish
Pages (from-to)192-205
Number of pages14
JournalCurrent Gene Therapy
Volume18
Issue number4
DOIs
StatePublished - 1 Jan 2018

Fingerprint

Oncolytic Virotherapy
Breast Neoplasms
Oncolytic Viruses
Therapeutics
Baltimore
Mortality
Neoplasms

Keywords

  • Breast cancer
  • Clinical trials
  • Oncolytic
  • Preclinical
  • Vectors
  • Virotherapy
  • Viruses

Cite this

O’bryan, Samia M. ; Mathis, James Michael. / Oncolytic virotherapy for breast cancer treatment. In: Current Gene Therapy. 2018 ; Vol. 18, No. 4. pp. 192-205.
@article{0c3bc93018bb408db95ae81ea39c358c,
title = "Oncolytic virotherapy for breast cancer treatment",
abstract = "Breast cancer continues to be a leading cause of mortality among women. While at an early stage, localized breast cancer is easily treated; however, advanced stages of disease continue to carry a high mortality rate. The discrepancy in treatment success highlights that current treatments are insufficient to treat advanced-stage breast cancer. As new and improved treatments have been sought, one therapeutic approach has gained considerable attention. Oncolytic viruses are uniquely capable of targeting cancer cells through intrinsic or engineered means. They come in many forms, mainly from four major virus groups as defined by the Baltimore classification system. These vectors can target and kill cancer cells, and even stimulate immunotherapeutic effects in patients. This review discusses not only individual oncolytic viruses pursued in the context of breast cancer treatment but also the emergence of combination therapies with current or new therapies, which has become a particularly promising strategy for treatment of breast cancer. Overall, oncolytic virotherapy is a promising strategy for increased treatment efficacy for advanced breast cancer and consequently provides a unique platform for personalized treatments in patients.",
keywords = "Breast cancer, Clinical trials, Oncolytic, Preclinical, Vectors, Virotherapy, Viruses",
author = "O’bryan, {Samia M.} and Mathis, {James Michael}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1566523218666180910163805",
language = "English",
volume = "18",
pages = "192--205",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

Oncolytic virotherapy for breast cancer treatment. / O’bryan, Samia M.; Mathis, James Michael.

In: Current Gene Therapy, Vol. 18, No. 4, 01.01.2018, p. 192-205.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Oncolytic virotherapy for breast cancer treatment

AU - O’bryan, Samia M.

AU - Mathis, James Michael

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Breast cancer continues to be a leading cause of mortality among women. While at an early stage, localized breast cancer is easily treated; however, advanced stages of disease continue to carry a high mortality rate. The discrepancy in treatment success highlights that current treatments are insufficient to treat advanced-stage breast cancer. As new and improved treatments have been sought, one therapeutic approach has gained considerable attention. Oncolytic viruses are uniquely capable of targeting cancer cells through intrinsic or engineered means. They come in many forms, mainly from four major virus groups as defined by the Baltimore classification system. These vectors can target and kill cancer cells, and even stimulate immunotherapeutic effects in patients. This review discusses not only individual oncolytic viruses pursued in the context of breast cancer treatment but also the emergence of combination therapies with current or new therapies, which has become a particularly promising strategy for treatment of breast cancer. Overall, oncolytic virotherapy is a promising strategy for increased treatment efficacy for advanced breast cancer and consequently provides a unique platform for personalized treatments in patients.

AB - Breast cancer continues to be a leading cause of mortality among women. While at an early stage, localized breast cancer is easily treated; however, advanced stages of disease continue to carry a high mortality rate. The discrepancy in treatment success highlights that current treatments are insufficient to treat advanced-stage breast cancer. As new and improved treatments have been sought, one therapeutic approach has gained considerable attention. Oncolytic viruses are uniquely capable of targeting cancer cells through intrinsic or engineered means. They come in many forms, mainly from four major virus groups as defined by the Baltimore classification system. These vectors can target and kill cancer cells, and even stimulate immunotherapeutic effects in patients. This review discusses not only individual oncolytic viruses pursued in the context of breast cancer treatment but also the emergence of combination therapies with current or new therapies, which has become a particularly promising strategy for treatment of breast cancer. Overall, oncolytic virotherapy is a promising strategy for increased treatment efficacy for advanced breast cancer and consequently provides a unique platform for personalized treatments in patients.

KW - Breast cancer

KW - Clinical trials

KW - Oncolytic

KW - Preclinical

KW - Vectors

KW - Virotherapy

KW - Viruses

UR - http://www.scopus.com/inward/record.url?scp=85054742616&partnerID=8YFLogxK

U2 - 10.2174/1566523218666180910163805

DO - 10.2174/1566523218666180910163805

M3 - Review article

VL - 18

SP - 192

EP - 205

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 4

ER -